Tempus AI (TEM) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
7 Apr, 2026Executive summary
Annual meeting scheduled for May 21, 2026, with voting open until May 20, 2026, at 10:59 PM Central Time.
Proxy materials are available online, and shareholders are encouraged to review them before voting.
Meeting will be held virtually, allowing remote participation and voting.
Voting matters and shareholder proposals
Election of nine directors to serve until the next annual meeting or until successors are qualified.
Ratification of PricewaterhouseCoopers LLP as independent auditor for the fiscal year ending December 31, 2026.
Advisory vote on the frequency of future shareholder votes regarding executive compensation.
Proxyholders may vote on other business that arises during the meeting.
Board of directors and corporate governance
Nine director nominees listed, including Eric Lefkofsky, Jennifer A. Doudna, and Scott Gottlieb, M.D.
Latest events from Tempus AI
- AI-powered diagnostics and data platform targets $2.5B+ revenue by 2028 with accelerating growth.TEM
Investor Day 202629 May 2026 - Profitability expected in 2025, driven by genomics, data, and high-margin AI applications.TEM
24th Annual Needham Virtual Healthcare Conference29 May 2026 - Revenue up 36% to $348.1M, net loss widens, guidance raised, and AI-driven growth accelerates.TEM
Q1 20265 May 2026 - Diagnostics and data segments show strong growth, fueled by AI and strategic partnerships.TEM
25th Annual Needham Virtual Healthcare Conference14 Apr 2026 - Proxy covers director elections, auditor ratification, and triennial say-on-pay, with insider voting control.TEM
Proxy filing7 Apr 2026 - AI-driven insights from proprietary clinical and molecular data are reshaping precision medicine.TEM
Morgan Stanley Technology, Media & Telecom Conference 20263 Mar 2026 - Q4 and 2025 revenue rose 83% year-over-year, with strong Diagnostics and Data growth.TEM
Q4 202524 Feb 2026 - Q2 revenue up 25% to $166M, net loss $552M on IPO costs, cash at $479.7M.TEM
Q2 20242 Feb 2026 - Q3 revenue up 33% YoY; Ambry Genetics acquisition expands growth and capabilities.TEM
Q3 202416 Jan 2026